Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer

NCT01274624 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

KRAS Mutant Metastatic Colorectal Cancer

Interventions

BIOLOGICAL: REOLYSIN®
DRUG: Irinotecan
DRUG: Leucovorin
DRUG: Fluorouracil (5-FU)
DRUG: Bevacizumab

Sponsor

Oncolytics Biotech

Collaborators

[object Object]